Send to:

Choose Destination
See comment in PubMed Commons below
Case Rep Oncol. 2013 Jan;6(1):45-9. doi: 10.1159/000346614. Epub 2013 Jan 19.

Non-hodgkin lymphoma after treatment with extended dosing temozolomide and radiotherapy for a glioblastoma: a case report.

Author information

  • 1Department of Medical Oncology, University of Hasselt, Diepenbeek, Belgium.


Temozolomide (TMZ) is an alkylating agent, used for the treatment of high-grade gliomas. This case report describes the development of a non-Hodgkin lymphoma in a patient treated with extended-dose temozolomide and radiotherapy. In addition to the possible mutagenic effect of temozolomide - as described for all alkylating agents - there might have been an immunosuppressive effect of TMZ. The pathological appearance of the lymphoma as well as the presence of a grade 3 lymphopenia early in treatment supports this hypothesis. As the use of TMZ increases, the awareness that TMZ may induce secondary malignancies should increase as well.


B-cell lymphoma; Diffuse large B-cell lymphoma; Epstein-Barr virus; Lymphopenia; Temozolomide

Free PMC Article
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for S. Karger AG, Basel, Switzerland Icon for PubMed Central
    Loading ...
    Write to the Help Desk